Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methoxy polyethylene glycol-epoetin beta
- Development stage
- Approved
- Lead developer
- Roche
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous
01
Overview
Methoxy polyethylene glycol-epoetin beta, marketed under the brand name Mircera, is a long-acting erythropoiesis-stimulating agent (ESA) developed by Roche. It is a continuous erythropoietin receptor activator (CERA) produced by the chemical modification of recombinant epoetin beta with a methoxy polyethylene glycol polymer (PEGylation). This modification results in a significantly longer half-life compared to traditional erythropoietins, allowing for less frequent dosing (once every two to four weeks). The drug works by binding to and activating the erythropoietin receptor on erythroid progenitor cells in the bone marrow, thereby stimulating red blood cell production. It is primarily indicated for the treatment of anemia associated with chronic kidney disease (CKD) in both dialysis and non-dialysis adult patients.
- Brand names
- Mircera
- Other names
- Continuous Erythropoietin Receptor ActivatorCERApegylated epoetin beta
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on methoxy polyethylene glycol-epoetin beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methoxy polyethylene glycol-epoetin beta.